



DOI: <https://doi.org/10.56936/18290825-2023.17.3-59>

## HYPOTENSIVE AND ANTIOXIDANT PROPERTIES OF GAMMA-HYDROXY ACID HYDRAZIDES

GHOCHIKYAN T.V., MARTIRYAN A.I., TADEVOSYAN L.G., PETROSYAN I.A.,  
GALSTYAN A.S.\*, SAMVELYAN M.A.

Faculty of Chemistry, Yerevan State University, Yerevan, Armenia

Received 15.12.2022; accepted for printing 5.06.2023

### ABSTRACT

A method has been proposed for the preparation of 4-hydroxybutanoic acid hydrazides for the first time. It has been established that the target products are obtained by the interaction of 2-substituted (*H*, alkyl, aralkyl, allyl, etc.)-4-substituted-4-butanolides with 85% aqueous solution hydrazine hydrate. Testing was carried out on white mongrel mice and reliably shown that the introduction of a hydroxypropyl residue into the composition of the synthesized hydrazides leads to new properties, namely hypotensive activity, not previously observed in compounds class of carboxylic acid hydrazides of various structures. The most active compounds have been selected and tested in rats and cats. It has been established that the lethal dose (lethal doses 50) of the proposed compounds ranges from 550-762 mg/kg and they exhibit superior activity compared to those used in the medical preparation "Dibazol".

In order to find new useful properties in a series of gamma-hydroxy acid hydrazides, their antioxidant features were studied by the method of competitive reactions. As a competitive acceptor, 4-nitroso-*N,N*-dimethylaniline was used.

According to the rate of discoloration of the last the reactivity of *H* radicals with respect to the studied compounds was determined. *H* radicals were initiated by photolysis of hydrogen peroxide (conc, 10<sup>-3</sup> mol/l), under exposure to ultraviolet radiation, at a wavelength of 313 nm. Initiation rate *H* radicals were measured by the rate of change in the optical density of para-Nitroso-*N,N*-dimethyl aniline in distilled water and in the presence of the studied compounds.

As a result of the research, it was found that all compounds of this series have antioxidant properties, and some of them are comparable with renowned antioxidant vitamin C.

**KEYWORDS:** gamma-hydroxycarboxylic acid hydrazides, cyclic esters, competitive reactions, hypotensive activity, antioxidant activity.

### INTRODUCTION

As is known, derivatives of organic acids, particularly hydrazides, are widely used as starting compounds in fine organic chemistry. The data on the useful properties of the latter are rather scanty. Recently it has been shown that some derivatives

of the naproxen series (S) that are acetohydrazides of various structures have antitumor activity against cell lines of human prostate carcinoma [Han M et al., 2018]. Some hydrazides of substituted benzoic acids also exhibit a similar property

### CITE THIS ARTICLE AS:

Ghochikyan T.V., Martiryan A.I., Tadevosyan L.G., Petrosyan I.A., Galstyan A.S., Samvelyan M.A. (2023). Hypotensive And Antioxidant Properties Of Gamma-Hydroxy Acid Hydrazides; The New Armenian Medical Journal, vol.17(3), p 59-65; <https://doi.org/10.56936/18290825-2023.17.3-59>

### ADDRESS FOR CORRESPONDENCE:

Armen S. Galstyan, PhD  
Faculty of Chemistry, Yerevan State University  
1 Alex Manoogian Street, Yerevan 0025, Armenia  
Tel.: (+374 60) 71-04-01  
E-mail: a\_galstyan@ysu.am

[Arjun H et al., 2019]. It was found that a number of hydrazonehydrazides showed antioxidant and antimicrobial activity [Afsah E et al., 2019]. In addition to the aforesaid, hydrazides of carboxylic acids are successfully used for the synthesis of heterocyclic compounds, in particular, oxadiazoles and 1,2,4-triazoles. The role of hydrazides in the synthesis of the latter is especially important, since numerous representatives of 1,2,4-triazoles are widely used in practical medicine – Voriconazole, Triazolam, Fluconazole, Itraconazole, Furaciline, Alprazolam, Estazolame and others.

The uniqueness of these compounds lies in the fact they are not found in natural raw material, easily obtained and have a wide range of application. The development of new methods for producing 1,2,4-triazoles is still under way [Khan T et al., 2019; Dolzhenko A et al., 2007; Gupta M, 2007; Song Y.-H, Young S, 2010]. Recent studies show that the biological properties of compounds are increasing from year to year. It was shown that various derivatives of 1,2,4-triazoles possessed antimicrobial [Koparir M et al., 2013], antitumor [Li YH et al., 2017; Zhang G, Hu Y, 2007], antibacterial [Gao F et al., 2019; Karnik A et al., 2006; Arafa W, 2010; Puthiyapurayil P et al., 2011; Zeydi M et al., 2017], fungicidal [Jian F et al., 2006; Song HX, Shi DQ, 2014] activities. For the first time it has been found that at a certain set of substituents in a molecule, the triazole derivatives show affinity for the human adenosine A3 receptor [Federico S et al., 2018] and exhibit insecticidal properties against *T. cinnabarinus* [Luo Y et al., 2007]. As can be seen from the data presented, studies in the field of various derivatives of 1,2,4-triazoles and their starting compounds are relevant and urgent.

Searches of literature data have shown that there are no data on *gamma*-hydroxy acid hydrazides. The interest in these compounds can be explained by the fact that the first representative of the homologous series – *gamma*-hydroxybutyric acid plays a crucial role in the human central nervous system, and the sodium salt of this acid is widely used in anesthesiology and ophthalmology. Based on the foregoing, it can be assumed that the introduction of the *gamma*-hydroxybutyric acid residue into the molecules of the biologically active substance can lead to manifestation of new

useful properties in this class of compounds.

The lack of data on the hydrazides mentioned can most likely be explained by the absence of a raw material base since *gamma*-hydroxy acids and their esters are unstable and *gamma*-hydroxybutyric acid even in aqueous solution is in equilibrium with a cyclic form.

## RESULTS AND DISCUSSION

Dihydrofuran-2(3H)-one (butyrolactone or butan-4-olide) is a cyclic ester of *gamma*-hydroxybutyric acid. Similarly, but under harsher conditions, other representatives of *gamma*-hydroxycarboxylic acids undergo cyclization to form dihydrofuran-2(3H)-ones of various structures. We previously synthesized a series of 2,4,4-trisubstituted-4-butanolides (**1a-k**) (fig.1) [Kochikyan T et al., 2003; Haroutunyan V et al., 2000].

Compounds **2a-k** [Ghochikyan T et al., 2023] were subjected to preliminary biological screening and it was established that some of those hydrazides showed hypotensive and antioxidant activities. The most promising compounds were studied in rats and cats. Specifically, the effect of com-




FIGURE 1. Schem synthesis of compaunds 2a-k radicals of compaunds is show in table 1

**TABLE 1**

Yields of compaunds 2a-k

Comp. #	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	Yield, (%)
<b>2a</b>	PrOCH <sub>2</sub>	H	Et	93
<b>2b</b>	<sup>t</sup> BuOCH <sub>2</sub>	H	H	90
<b>2c</b>	<sup>t</sup> BuOCH <sub>2</sub>	H	Bu	85
<b>2d</b>	AmOCH <sub>2</sub>	H	H	89
<b>2e</b>	Am	H	H	85
<b>2f</b>	PrOCH <sub>2</sub>	H	Bu	83
<b>2g</b>	<sup>t</sup> BuOCH <sub>2</sub>	H	Bn	87
<b>2h</b>	<sup>i</sup> AmOCH <sub>2</sub>	H	Bn	91
<b>2i</b>	Am	H	All	94
<b>2j</b>	Me	Me	Bu	86
<b>2k</b>	Me	H	<sup>i</sup> Am	80

pounds **2b** and **2d** on the level of systemic blood pressure (SBP) was studied in the usual way in experiments on anesthetized (Nembutal 50 mg/kg) animals. In a separate series of experiments on the anesthetized cats, the effect of substances on the central hemodynamics was studied; SBP was recorded in the common carotid artery. Minute blood volume was studied by thermode-lation. The heart rate (HR) was calculated by the electrocardiogram recorded in the 2nd standard lead. The total peripheral resistance (TPR), stroke volume (SV) and the left ventricle (LVF) work were determined by calculation.

Acute toxicity was studied in experiments on white mice with intraperitoneal administration according to the method of Miller and Teitner. Acute toxicity of **4b** was 762 mg/kg, and that of **2d** – 550 mg/kg.

The test substances were administered intravenously in an aqueous solution at doses of 10, 20, 50 and 100 mg/kg.

Compound **2b** at doses of 20 and 50 mg/kg reduced SBP moderately and briefly, at a dose of 100 mg/kg more pronounced hypotension was observed (Table 2). Compound **2d** significantly exceeded compound **2b** in hypotensive activity. So already a dose of 10 mg/kg caused a distinct decrease in SBP. Increase of the dose to 20 and 50 mg/kg led to a significant strengthening of the hypotensive effect (Table 2).

In experiments on anesthetized cats, compound **2d** caused a less hypotensive effect than in experiments on rats. This can probably be explained by unequal species sensitivity to this substance. The decrease in SBP after administration of **2d** in experiments on cats is due to a decrease in TPR, while multivesicular body (MVB) in-

creased slightly (Table 3). Heart rate and LVF after administration of **2d** at doses of 25 and 50 mg/kg were practically unchanged.

Thus, compounds **2b** and **2d** have pronounced hypotensive activity being low toxic at that (Table 4).

In order to find new useful properties in a series of gamma-hydroxy acid hydrazides, their antioxi-

TABLE 2

The effect of compounds **2b** and **2d** on the level of SBP (experiments on rats)

Comp. #	Dose mg/kg	Number of experiences	Changes in SBP* after administration of the substance (in% to the initial) after a time (min)				
			5	15	30	45	60
<b>2b</b>	20	5	-21±6**	-13±5	-8±5	-3±4	-1±4
	50	5	-18±5**	-9±3	-8±4	-7±2	-5±2
	100	5	-26±6**	-16±7	-14±5	-13±5	-11±5
<b>2d</b>	20	5	-17±4**	-13±6	-9±3	-3±3	-3±3
	50	5	-25±7**	-14±4**	-12±4	-10±4	-6±2
	100	5	-35±8**	-27±8**	-19±6**	-18±6**	-11±5

Notes: \* – “-” decrease, “+” increase SBP, \*\* – changes SBP statistically reliable

TABLE 3

The effect of compound **2d** on the level of SBP (experiments on cats)

Dose (mg/kg)	Time from start (min)	Changes in SBP* after administration of the substance (in % to the initial) after a time (min)					
		SBP	HR	MVB	TPR	SV	LVF
25	ID	170±20.2	148±12.2	686±42.6	15156±139.8	12.3±2.3	14103±96.2
	5	-1.2±0.4	-1.9±3.9	-38.7±6.4	+63.3±6.4	+38.4±4.3	-39.0±9.2
	15	-1.2±0.4	-1.9±4.2	-29.9±6.8	+40.65±5.8	-29.5±4.8	-39.0±9.2
	30	-1.8±0.6	-3.6±3.8	-17.6±8.9	+31.9±12.4	-16.2±3.6	-17.3±6.4
	45	-1.9±0.6	-4.6±3.6	-15.8±7.4	+19.6±7.9	-10.1±4.2	-12.2±6.9
	60	-2.0±0.5	-4.6±3.4	+24.8±12.6	-16.4±9.6	+12.8±6.4	+11.8±6.2
50	ID	140±20.6	140±25.3	292±42.6	31169±83.4	2.3±2.3	3577±64.3
	5	-6.4±3.6	-0.8±1.2	+4.1±3.8	-9.7±4.3	+15.3±6.2	+3.7±3.5
	15	-14.6±4.9	-0.8±1.2	+0.5±3.2	-16.8±3.7	+6.9±2.4	-18.3±6.8
	30	-14.6±4.9	-0.4±0.2	+6.3±2.4	-21.4±6.2	+3.4±1.8	-1.5±0.9
	45	-17.5±5.3	0	+16.2±4.6	-29.5±4.3	+13.9±3.3	-0.9±0.2
	60	-17.6±5.4	0	+12.4±6.2	-38.0±5.5	+12.5±3.8	+6.9±4.3

Notes: \* – “-” decrease, “+” increase, SBP – systemic blood pressure, HR – Heart rate, MVB – multivesicular body, TPR – total peripheral resistance, SV – stroke volume, LVF – left ventricle, ID – Initial data

TABLE 4

Comparative effect of compound **2b** (experiments on cats) (in comparable doses of 1/10 of LD<sub>50</sub>)

Dose (mg/kg)	Time from start (min)	Changes in SBP* after administration of the substance (in % to the initial) after a time (min)					
		SBP	HR	MVB	TPR	SV	LVF
<b>Compound 2b</b>							
60	ID	125±15.3	200±13.3	184±58	50497±320	1.2±0.3	2931±305
	5	-4.4±1.3	-1.2±4.3	-6.7±7.3	+30.5±12.3	-7.2±5.8	-9.5±1.5
	15	-4.4±1.3	-5.5±6.1	-8.5±3.5	+40.2±8.7	-12.6±3.4	-10.5±4.2
	30	-8.7±2.9	-9.9±9.0	-22.0±9.8	+55.8±14.6	-18.7±9.8	-18.7±9.8
	45	-8.7±2.9	-9.9±9.0	-22.0±9.8	+55.8±14.6	-18.7±9.8	-18.7±9.8
	60	-12.0±4.0	-9.9±9.0	-30.6±12.4	+50.3±6.7	-18.7±6.4	-20.5±7.5
<b>Dibazole</b>							
60	ID	140±4.6	200±18.5	328±12.6	32012±159.8	2.4±0.7	0.7±0.1
	5	-21.4±6.8	-10.6±8.3	-15.2±3.8	-27.3±6.2	-21.9±3.6	-30.9±5.6
	15	-7.8±2.4	-7.1±8.1	-23.8±1.6	-13.8±3.2	-29.8±5.4	-10.4±8.7
	30	-4.2±3.8	-1.3±0.9	-34.3±6.5	-1.9±1.8	-59.6±8.7	-12.1±8.7
	45	-1.5±2.2	+0.7±1.2	-19.4±5.4	36.7±6.4	-27.6±10.	-4.3±3.2
	60	+5.1±4.3	+2.4±1.3	-17.4±3.6	-63.5±9.8	+21.3±9.7	+9.9±7.8

NOTES: \* – “-” decrease, “+” increase, SBP – systemic blood pressure, HR - Heart rate, MVB – multivesicular body, TPR – total peripheral resistance, SV – stroke volume, LVF – left ventricle, ID - Initial data

dant features were studied by the method of competitive reactions. As a competitive acceptor, 4-nitroso-N,N-dimethylaniline (PNDMA) was used, by the rate of discoloration of which the reactivity of H radicals in relation to compounds **2a-k** was determined. H was initiated by the photolysis of H<sub>2</sub>O<sub>2</sub> (10<sup>-3</sup> mol/l) under the influence of UV radiation at λ = 313 nm. The rate of H initiation was measured by the rate of change in the optical density of PNDMA in distilled water (**2a-k**).

The kinetic data of the effect of compounds of various concentrations on the optical density of PNDMA depending on the irradiation time are given below (Fig. 2).

Based on experimental data (Fig. 2,3) according to [Bielski B et al., 1985; Ernestova L, 1988; Simonsen M et al., 2010; Galstyan A et al., 2018] the rate constants were calculated by equation (1):

$$k_{OH+P} = 1.25 \times 10^{10} \times \frac{[PNDMA]}{[P]} \times \left[ \frac{W_1}{W_2} - 1 \right] \left( \frac{l}{mol \times sec} \right)$$

where 1.25×10<sup>10</sup> is the rate constant of the interaction of H radicals with PNDMA, [P] is the concentration of compounds **2a-k**, W<sub>1</sub> and W<sub>2</sub> are the rates of PNDMA discoloration in distilled water and in the presence of the studied compounds, respectively.

The following data for the reaction rate con-

stant of interaction of H radicals and the test substance were obtained (Table 5).

### CONCLUSION

For the first time, a method for producing 4-hydroxybutanoic acid hydrazides is proposed. It was found that the target products are obtained on the basis of 2-substituted (H, alkyl, aralkyl, allyl, etc.) – 4,4-disubstituted-4-butanolides, which undergo hy-

TABLE 5

The reaction rate constant of the interaction of H radicals and the test compounds were obtained

Compound #	Reaction rate constant for interaction of H radicals + test compound
<b>2a</b>	3.92×10 <sup>8</sup>
<b>2b</b>	4.82×10 <sup>8</sup>
<b>2c</b>	4.86×10 <sup>8</sup>
<b>2d</b>	4.95×10 <sup>8</sup>
<b>2e</b>	1.75×10 <sup>8</sup>
<b>2f</b>	5.25×10 <sup>8</sup>
<b>2g</b>	6.2×10 <sup>8</sup>
<b>2h</b>	2.7×10 <sup>8</sup>
<b>2i</b>	4.0×10 <sup>8</sup>
<b>2j</b>	1.71×10 <sup>8</sup>
<b>2k</b>	0.965×10 <sup>8</sup>
Ascorbic acid (control)	9.45×10 <sup>9</sup>




FIGURE 2. Dependence of optical density of PNDMA vs the time of UV irradiation ( $\lambda = 313 \text{ nm}$ ) at various concentrations of compounds 2a-k




FIGURE 3. The dependence of the rate of PNDMA decolouration (in relative units) on concentration

drazinolytic with 85% solution of hydrazine hydrate.

Preliminary screening established that newly synthesized compounds exhibited hypotensive activity. The selected, most active compounds were tested on rats and cats. It has been reliably established that the proposed compounds exceed in activity the drug *Dibazole* used in medical practice.

By the method of competitive reactions, it has been found that the proposed compounds also exhibit significant antioxidant activity.

### Experimental Section

The most promising compounds were studied in rats and cats. Specifically, the effect of compounds **4b** and **4d** (fig.4) on the level of systemic blood pressure was studied in the usual way in experiments on anesthetized (Nembutal 50 mg/kg) animals. In a separate series of experiments on the anesthetized cats, the effect of substances on the central hemodynamics was studied; SBP was re-




FIGURE 4. Structures of compounds 4b and 4d

corded in the common carotid artery. Minute blood volume was studied by thermolabeling. The heart rate was calculated by the electrocardiogram recorded in the 2nd standard lead. The total peripheral resistance, stroke volume and the left ventricle work were determined by calculation.

Acute toxicity was studied in experiments on white mice with intraperitoneal administration according to the method of Miller and Teitner. Acute toxicity of **2b** was 762 mg/kg, and that of **2d** – 550 mg/kg.

The test substances were administered intravenously in an aqueous solution at doses of 10, 20, 50 and 100 mg/kg.

### REFERENCES

1. Afsah EM, Abdel-Galil E, Youssef I, Elsaedy YH (2019). Synthesis and Biological Activity of Novel Hydrazide-Hydrazones Incorporating Piperidine and Piperazine Moieties and Related Mannich Bases. *American Journal of Chemistry and Materials Science*. 6: 58-65
2. Arafa WAA (2010). Preparation and evaluation of antibacterial activity of some new 1,2,4-triazole derivatives. *J. Heter. Chem.* 47: 1109-1115 <https://doi.org/10.1002/jhet.431>.
3. Arjun HA, Elancheran R, Manikandan N, Lakshmithendral K, Ramanathan M., et al (2019). *Front. Chem.* 7: 474 <https://doi.org/10.3389/fchem.2019.00474>
4. Bielski BHJ, Cabelli DE, Arudi RL, Ross AB (1985). Reactivity of HO<sub>2</sub>/O<sub>2</sub>- Radicals in Aqueous Solution. *J. Phys. Chem. Ref. Data*. 14: 1041-1100 <https://doi.org/10.1063/1.555739>.
5. Dolzhenko AV, Dolzhenko AV, Chui WK (2007). Practical synthesis of regioisomeric 5(7)-amino-6,7(4,5)-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines. *Tetrahedron*. 63: 12888-12895 <https://doi.org/10.1016/j.tet.2007.10.046>
6. Ernestova LS (1988). Water Quality Indicators. In book "Ecological chemistry of the aquatic environment", M. 256-277
7. Federico S, Margiotta E, Salmaso V, Pastorin G, Kachler S., et al (2018). [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A<sub>3</sub> adenosine receptor subtype. *Eur. J. Med. Chem.* 157: 837-851 <https://doi.org/10.1016/j.ejmech.2018.08.042>
8. Galstyan AS, Martiryan AI, Grigoryan KR, Ghazaryan AG, Samvelyan MA., et al (2018). Synthesis of Carvone-Derived 1,2,3-Triazoles Study of Their Antioxidant Properties and Interaction with Bovine Serum Albumin. *Molecules*. 23: 2991 <https://doi.org/10.3390/molecules23112991>
9. Gao F, Wang T, Xiao J, Huang G (2019). Antibacterial activity study of 1,2,4-triazole derivatives. *Eur. J. Med. Chem.* 173: 274-281 <https://doi.org/10.1016/j.ejmech.2019.04.043>
10. Ghochikyan TV, Galstyan AS, Samvelyan MA (2003). A new method for the preparation of hydrazides of substituted gamma-hydroxybutanoic acids. *Proc. YSU B: Chem. Biol. Sci.* 57: 68-76 <https://doi.org/10.46991/PYSU:B/2023.57.2.068>
11. Gupta M (2007). Synthesis and antifungal activity of novel 3,6-diaryl-5H-[1,2,4]triazolo[4,3-b][1,2,4]triazepines. *J. Het. Chem.* 44: 1023-1027 <https://doi.org/10.1002/jhet.5570440508>.

12. Han MI, Cumaoglu A, Küçükgülzel SG (2018). Synthesis and characterization of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-Naproxen as anticancer agents. *Marmara Pharm. J.* 22: 559-569 <http://dx.doi.org/10.12991/jrp.2018.98>
13. Haroutunyan VS, Kochikyan TV, Haroutunyan EV, Avetisyan AA (2000). [One-stage method for obtaining 2-carbethoxy-2,4-disubstituted-4-pentanolids] [Published in Russian]. *Chemical Journal of Armenia.* 53: 121-122.
14. Jian F, Xiao H, Zhu Ch, Xu L (2006). Synthesis, structure and biological activities of [ $\alpha$ -(alkylcarbonyl)-2-(1,2,4-triazol-1-yl)] ethyl-N,N-dialkyldithiocarbamate derivatives. *J. Heter. Chem.* 43: 925-929 <https://doi.org/10.1002/jhet.5570430417>.
15. Karnik AV, Malviya NJ, Kulkarni AM, Jaini D, Jadhav BL (2006). Synthesis and antibacterial studies of 6-aryl-2,2a-dihydro-naphtho-[2',1'-5,6]pyrano[4,3-e][1,2,4]triazolo[3,4-b][1,3,4]thiadiazine and its derivatives. *J. Heter. Chem.* 43: 489-493 <https://doi.org/10.1002/jhet.5570430236>.
16. Khan T, Yadav R, Gound SS (2018). An Efficient Synthesis and Antibacterial Activity of Some Novel 2-Azetidinone Derivatives of 4H-1,2,4-Triazoles Under Mild Conditions. *J. Het. Chem.* 55: 1042-1047 <https://doi.org/10.1002/jhet.3136>
17. Kochikyan TV, Samvelyan MA, Arutyunyan VS, Avetisyan AA (2003). Synthesis and Some Transformations of Ethyl 5-Alkoxy-methyl-3-(2-methyl-3-oxobutyl)-2-oxotetrahydrofuran-3-carboxylates. *Russ. J. Org. Chem.* 39: 1329-1333 <https://doi.org/10.1023/B:RUJO.0000010223.97769.33>
18. Koparir M, Orek C, Parlak AE, Söylemez A, Koparir P., et al (2013). Synthesis and biological activities of some novel aminomethyl derivatives of 4-substituted-5-(2-thienyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones. *Eur. J. Med. Chem.* 63: 340-346 <https://doi.org/10.1016/j.ejmech.2013.02.025>
19. Li YH, Zhang B, Yang HK, Li Q, Diao PCh., et al (2017). *Eur. J. Med. Chem.* 125: 1098-1106 <https://doi.org/10.1016/j.ejmech.2016.10.051>
20. Luo YP, Lin L, Yang GF (2007). Design and synthesis of diheterocyclic compounds containing tetrazolinone and 1,2,4-triazole. *J. Heter. Chem.* 44: 937-943 <https://doi.org/10.1002/jhet.5570440433>
21. Puthiyapurayil P, Poojary B, Kumar S, Hunnur R (2011). Synthesis and biological activities of a novel series of 3,6-disubstituted-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles containing gem-dimethylbenzyl moiety. *J. Heter. Chem.* 48: 998-1005 <https://doi.org/10.1002/jhet.674>.
22. Simonsen ME, Muff J, Bennedsen LR, Kowalski KP, Søgaaard EG (2010). Photocatalytic bleaching of p-nitrosodimethylaniline and a comparison to the performance of other AOP technologies. *Journal of Photochemistry and Photobiology A: Chemistry.* 216: 244-249 <https://doi.org/10.1016/j.jphotochem.2010.07.008>
23. Song HX, Shi DQ (2014). Synthesis and Fungicidal Activity of (E)- $\alpha$ -(Methoxyimino)benzene-acetate Derivatives Containing 1,2,4-Triazole Schiff Base Side Chain. *J. Heter. Chem.* 51: 1345-1348 <https://doi.org/10.1002/jhet.1795>.
24. Song YH, Young SH (2010). Synthesis of new sulfur-linked 1,2,4-triazolothienopyrimidine and 1,2,4-triazolopyrazolopyrimidine derivatives containing fused heterocyclic pyrimidines. *J. Het. Chem.* 47: 1183-1187 <https://doi.org/10.1002/jhet.461>.
25. Zeydi MM, Montazeri N, Fouladi M (2017). Synthesis and Evaluation of Novel [1,2,4]Triazolo-[1,5-c]quinazoline Derivatives as Antibacterial Agents. *J. Heter. Chem.* 54: 3549-3553 <https://doi.org/10.1002/jhet.2979>.
26. Zhang G, Hu Y (2007). Synthesis and antitumor activities of 2-(substituted)phenyl-1,2,4-triazolo[1,5-a]pyridines. *J Heter Chem.* 44: 919-922 <https://doi.org/10.1002/jhet.5570440428>



**CONTENTS**

4. **AVAGYAN M., KAGER L., ZOHRABYAN D., SAFARYAN L., TANANYAN A., MAMUNTS D., PAPYAN R., ARAKELYAN J., VARDEVANYAN H., MKHITARYAN S., TAMAMYAN G., BARDAKHCHYAN S.**  
SECONDARY MALIGNANCY IN GIANT CELL TUMOR OF THE SKULL BASE AFTER DENOSUMAB TREATMENT: CASE REPORT
11. **NURDIANA N., WINARSIH S., TRI ENDHARTI A., HANDAYANI S.**  
HOLOTHURIN AND CASPOFUNGIN-INDUCED ALTERATIONS IN TOLL-LIKE RECEPTOR 4 EXPRESSION IN THE VAGINA OF RATTUS NORVEGICUS WISTAR WITH CANDIDIASIS
20. **GAISENOK O.V.**  
MYOCARDIAL INFARCTION AT A YOUNG AGE: ANALYSIS OF CLINICAL CASES FROM THE DUPLEX REGISTRY DATABASE
25. **GAVANJI S., BAKHTARI A., BAGHSHAHI H., BADRIPOUR N., HAMAMI CHAMGORDANI Z.**  
CYTOTOXICITY EFFECTS OF ETHANOLIC EXTRACT OF PUNICA GRANATUM VAR. PLENIFLORA ON MCF-7 COMPARED WITH L929 CELLS
31. **BANJARI I., HAN S., AL-TAWIL N., ĆORIĆ N., BALKIĆ WIDMANN J.**  
STROKE RISK ASSESSMENT AND DIET-RELATED RISK FACTORS – COMPARISON OF TWO CITIES FROM BOSNIA AND HERZEGOVINA
40. **SANI M., HOKMABADI M.E.**  
THE EFFECT OF GALLIC ACID AS A PLANT POLYPHENOL COMPOUND ON OXIDATIVE STRESS INDUCED IN ALZHEIMER'S NEURODEGENERATIVE DISEASE
51. **EBRAHIMZADEH KOUR B., JAMBARSANG S., KARIMPOUR F., HOSSEINI S.E., RAMAZANI V., MOZAFFARI-KHOSRAVI H.**  
INFLAMMATORY AND STRESS OXIDATIVE IMPROVING POTENTIAL OF CHROMIUM SUPPLEMENTATION: PROTOCOL FOR A SYSTEMATIC REVIEW AND META ANALYSIS OF RANDOMIZED CLINICAL TRIALS
59. **GHOCHIKYAN T.V., MARTIRYAN A.I., TADEVOSYAN L.G., PETROSYAN I.A., GALSTYAN A.S., SAMVELYAN M.A.**  
HYPOTENSIVE AND ANTIOXIDANT PROPERTIES OF GAMMA-HYDROXY ACID HYDRAZIDES
66. **HOVHANNISYAN H.G., PASHAYAN M.M., BARSEGHYAN A.H., GRIGORYAN G.G., GABOYAN E.H., DANIELYAN L.V.**  
HEALTH PROMOTING POTENTIALS OF ARMENIAN FUNCTIONAL SOUR MILK "NARINE" AND ITS STARTER LACTOBACILLUS HELVETICUS MDC 9602
74. **SANI M., HOKMABADI M.E.**  
DESCRIBING THE GINGER PLANT AND ITS EFFECTIVE INGREDIENTS ALONG WITH ITS THERAPEUTIC PROPERTIES IN VARIOUS COMPLICATIONS
84. **REVENKO N.A., SIZOVA O.A., MARCHUKOVA A.YU., KALADZE N.N., ITSKOVA E.A.**  
EFFECTIVENESS OF COMBINED REHABILITATION THERAPY IN KIDS WITH METABOLIC SYNDROME
91. **KUMAR-ANMOL K., CHANDRASEKARAN M.S., ADARSHA G.K., NITIN BHAT N., RAO R.**  
A RARE CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA COMPLICATED BY MACROVASCULAR EVENTS
95. **ALHOQAIL A.A., ALSAAD S.M.**  
ASSOCIATION BETWEEN POSTPARTUM DEPRESSION AND SLEEP QUALITY AND ITS RELATED FACTORS
105. **MANUKYAN N.V., TAMAMYAN G.N., AVETISYAN A.A., JILAVYAN S.A., SAGHATELYAN T.S.**  
A REVIEW OF CHALLENGES AND PROSPECTS OF MOBILE MAMMOGRAPHY SCREENING IN DEVELOPING COUNTRIES
119. **QADAH W.A.**  
THE IMPACT OF SOCIAL MEDIA ADDICTION ON SELF-ESTEEM AND LIFE SATISFACTION AMONG STUDENTS IN KING ABDUL AZIZ UNIVERSITY AND FAKEEH COLLEGE FOR MEDICAL SCIENCES IN JEDDAH: CROSS-SECTIONAL STUDY



The Journal is founded by  
Yerevan State Medical  
University after M. Heratsi.

## Rector of YSMU

Armen A. Muradyan

## Address for correspondence:

Yerevan State Medical University  
2 Koryun Street, Yerevan 0025,  
Republic of Armenia

## Phones:

(+37410) 582532 YSMU

(+37493 588697 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

*Our journal is registered in the databases of Scopus,  
EBSCO and Thomson Reuters (in the registration process)*



SCOPUS



EBSCO

REUTERS

**Copy editor: Tatevik R. Movsisyan**

Printed in "LAS Print" LLC  
Director: Suren A. Simonyan  
Armenia, 0023, Yerevan,  
Acharyan St. 44 Bulding,  
Phone: (+374 10) 62 76 12,  
E-mail: las.print@yahoo.com

## Editor-in-Chief

Arto V. Zilfyan (Yerevan, Armenia)

## Deputy Editors

Hovhannes M. Manvelyan (Yerevan, Armenia)

Hamayak S. Sisakyan (Yerevan, Armenia)

## Executive Secretary

Stepan A. Avagyan (Yerevan, Armenia)

## Editorial Board

Armen A. Muradyan (Yerevan, Armenia)

Drastamat N. Khudaverdyan (Yerevan, Armenia)

Levon M. Mkrtchyan (Yerevan, Armenia)

## Foregin Members of the Editorial Board

Carsten N. GUTT (Memmingen, Germany)

Muhammad MIFTAHUSSURUR (Indonesia)

Alexander WOODMAN (Dharhan, Saudi Arabia)

Hesam Adin Atashi (Tehran, Iran)

## Coordinating Editor (for this number)

NAREK V. MANUKYAN (Yerevan, Armenia)

## Editorial Advisory Council

Ara S. Babloyan (Yerevan, Armenia)

Aram Chobanian (Boston, USA)

Luciana Dini (Lecce, Italy)

Azat A. Engibaryan (Yerevan, Armenia)

Ruben V. Fanarjyan (Yerevan, Armenia)

Gerasimos Filippatos (Athens, Greece)

Gabriele Fragasso (Milan, Italy)

Samvel G. Galstyan (Yerevan, Armenia)

Arthur A. Grigorian (Macon, Georgia, USA)

Armen Dz. Hambardzumyan (Yerevan, Armenia)

Seyran P. Kocharyan (Yerevan, Armenia)

Aleksandr S. Malayan (Yerevan, Armenia)

Mikhail Z. Narimanyan (Yerevan, Armenia)

Levon N. Nazarian (Philadelphia, USA)

Yumei Niu (Harbin, China)

Linda F. Noble-Haeusslein (San Francisco, USA)

Arthur K. Shukuryan (Yerevan, Armenia)

Suren A. Stepanyan (Yerevan, Armenia)

Gevorg N. Tamamyanyan (Yerevan, Armenia)

Hakob V. Topchyan (Yerevan, Armenia)

Alexander Tsiskaridze (Tbilisi, Georgia)

Konstantin B. Yenkovyan (Yerevan, Armenia)

Peijun Wang (Harbin, China)